Natera Inc
NTRA230.630USD
+5.080+2.25%
收盘 11/21, 16:00（美东）报价延迟15分钟
31.35B总市值
亏损市盈率 TTM
关于 Natera Inc 公司
Natera, Inc. 是一家诊断公司，专注于分子检测服务的开发和商业化，将其技术应用于女性健康、肿瘤学和器官健康领域。其无细胞脱氧核糖核酸 (cfDNA) 技术结合了其分子检测，可从小到单细胞的样本中可靠地测量整个基因组的许多信息区域。该公司的产品包括 Panorama 无创产前检测 (NIPT)、Vistara、Horizon 携带者筛查、Spectrum 植入前遗传学、Anora 流产检测、Empower 和 Prospera。该公司还提供 Constellation，这是一个基于云的软件平台，使实验室客户能够通过云访问公司的算法和生物信息学，以验证和启动基于公司技术的测试。其 NIPT 可筛查胎儿和双胞胎妊娠的染色体异常，通常需要从母亲抽血。
Natera Inc简介
公司代码NTRA
公司名称Natera Inc
上市日期Jul 02, 2015
CEOMr. Steven Leonard (Steve) Chapman
员工数量4424
证券类型Ordinary Share
年结日Jul 02
公司地址13011 Mccallen Pass
城市AUSTIN
上市交易所NASDAQ Global Select Consolidated
国家United States of America
邮编78753
电话16502499090
网址https://www.natera.com/
公司代码NTRA
上市日期Jul 02, 2015
CEOMr. Steven Leonard (Steve) Chapman
Natera Inc公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Matthew Rabinowitz, Ph.D.
Dr. Matthew Rabinowitz, Ph.D.
Executive Chairman of the Board, Co-Founder
Executive Chairman of the Board, Co-Founder
2.28M
-1.72%
Mr. Roelof Frederick Botha
Mr. Roelof Frederick Botha
Lead Independent Director
Lead Independent Director
1.23M
+0.01%
Mr. Jonathan Sheena
Mr. Jonathan Sheena
Co-Founder, Director
Co-Founder, Director
305.25K
-1.00%
Mr. Daniel A Rabinowitz
Mr. Daniel A Rabinowitz
Secretary, Chief Legal Officer
Secretary, Chief Legal Officer
150.99K
-1.05%
Mr. John Fesko
Mr. John Fesko
President, Chief Business Officer
President, Chief Business Officer
86.09K
-2.32%
Herman Rosenman, CPA
Herman Rosenman, CPA
Independent Director
Independent Director
65.67K
+0.23%
Mr. Solomon Moshkevich
Mr. Solomon Moshkevich
President - Clinical Diagnostics
President - Clinical Diagnostics
37.71K
-7.37%
Dr. Monica Bertagnolli, M.D.
Dr. Monica Bertagnolli, M.D.
Independent Director
Independent Director
6.22K
+1.52%
Dr. Rowan E. Chapman, Ph.D.
Dr. Rowan E. Chapman, Ph.D.
Independent Director
Independent Director
3.18K
+4.20%
Mr. Steven Leonard (Steve) Chapman
Mr. Steven Leonard (Steve) Chapman
Chief Executive Officer, Director
Chief Executive Officer, Director
3.17K
-28.17%
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Matthew Rabinowitz, Ph.D.
Dr. Matthew Rabinowitz, Ph.D.
Executive Chairman of the Board, Co-Founder
Executive Chairman of the Board, Co-Founder
2.28M
-1.72%
Mr. Roelof Frederick Botha
Mr. Roelof Frederick Botha
Lead Independent Director
Lead Independent Director
1.23M
+0.01%
Mr. Jonathan Sheena
Mr. Jonathan Sheena
Co-Founder, Director
Co-Founder, Director
305.25K
-1.00%
Mr. Daniel A Rabinowitz
Mr. Daniel A Rabinowitz
Secretary, Chief Legal Officer
Secretary, Chief Legal Officer
150.99K
-1.05%
Mr. John Fesko
Mr. John Fesko
President, Chief Business Officer
President, Chief Business Officer
86.09K
-2.32%
Herman Rosenman, CPA
Herman Rosenman, CPA
Independent Director
Independent Director
65.67K
+0.23%
收入明细
单位: USD更新时间: 10月6日 周一
单位: USD更新时间: 10月6日 周一
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
业务USD
名称
营收
占比
Insurance carriers
516.99M
94.58%
Laboratory and other partners
22.17M
4.06%
Patients
7.44M
1.36%
地区USD
名称
营收
占比
United States
537.80M
98.39%
Europe, Middle East, India, Africa
5.41M
0.99%
Asia Pacific and Other
1.82M
0.33%
Americas, excluding U.S
1.57M
0.29%
业务
地区
业务USD
名称
营收
占比
Insurance carriers
516.99M
94.58%
Laboratory and other partners
22.17M
4.06%
Patients
7.44M
1.36%
股东统计
更新时间: 11月16日 周日
更新时间: 11月16日 周日
持股股东
股东类型
持股股东
持股股东
占比
The Vanguard Group, Inc.
8.94%
T. Rowe Price Associates, Inc.
8.57%
JP Morgan Asset Management
7.02%
BlackRock Institutional Trust Company, N.A.
4.92%
Farallon Capital Management, L.L.C.
3.08%
其他
67.48%
持股股东
持股股东
占比
The Vanguard Group, Inc.
8.94%
T. Rowe Price Associates, Inc.
8.57%
JP Morgan Asset Management
7.02%
BlackRock Institutional Trust Company, N.A.
4.92%
Farallon Capital Management, L.L.C.
3.08%
其他
67.48%
股东类型
持股股东
占比
Investment Advisor
46.30%
Investment Advisor/Hedge Fund
27.01%
Hedge Fund
12.75%
Individual Investor
3.07%
Family Office
2.73%
Family Office
2.73%
Family Office
2.46%
Bank and Trust
1.98%
Research Firm
1.60%
机构持股
更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
1200
128.93M
93.94%
-2.81M
2025Q2
1137
131.96M
96.64%
-402.16K
2025Q1
1129
133.60M
97.90%
+2.21M
2024Q4
1001
128.40M
95.17%
-537.76K
2024Q3
896
125.06M
100.75%
-6.81M
2024Q2
850
125.13M
101.89%
-7.92M
2024Q1
798
124.30M
101.71%
-6.12M
2023Q4
781
119.55M
99.60%
-13.66M
2023Q3
787
122.52M
102.97%
-5.30M
2023Q2
792
116.72M
102.40%
-10.10M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
The Vanguard Group, Inc.
12.62M
9.2%
+279.77K
+2.27%
Jun 30, 2025
T. Rowe Price Associates, Inc.
12.07M
8.79%
+1.64M
+15.72%
Jun 30, 2025
JP Morgan Asset Management
8.92M
6.5%
+2.53M
+39.53%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
6.78M
4.94%
+101.02K
+1.51%
Jun 30, 2025
Farallon Capital Management, L.L.C.
4.82M
3.51%
+274.00K
+6.02%
Jun 30, 2025
State Street Investment Management (US)
3.32M
2.42%
-53.04K
-1.57%
Jun 30, 2025
Duquesne Family Office LLC
3.09M
2.25%
-317.14K
-9.32%
Jun 30, 2025
Geode Capital Management, L.L.C.
2.55M
1.86%
+166.77K
+6.99%
Jun 30, 2025
Franklin Advisers, Inc.
1.93M
1.41%
+330.96K
+20.65%
Jun 30, 2025
Wellington Management Company, LLP
2.63M
1.92%
-426.00K
-13.92%
Jun 30, 2025
查看更多
持股ETF
更新时间: 11月6日 周四
更新时间: 11月6日 周四
机构名称
占比
Franklin Genomic Advancements ETF
6.11%
Alger Weatherbie Enduring Growth ETF
5.61%
VanEck Biotech ETF
4.16%
Alger 35 ETF
4.03%
ARK Genomic Revolution ETF
3.94%
Global X Genomics & Biotechnology ETF
3.85%
First Trust Nasdaq Lux Digi Health Solutions ETF
3.83%
Invesco Dorsey Wright Healthcare Momentum ETF
3.38%
TrueShares Technology, AI & Deep Learning ETF
3.21%
First Trust NYSE Arca Biotechnology Index Fund
3.12%
查看更多
Franklin Genomic Advancements ETF
占比6.11%
Alger Weatherbie Enduring Growth ETF
占比5.61%
VanEck Biotech ETF
占比4.16%
Alger 35 ETF
占比4.03%
ARK Genomic Revolution ETF
占比3.94%
Global X Genomics & Biotechnology ETF
占比3.85%
First Trust Nasdaq Lux Digi Health Solutions ETF
占比3.83%
Invesco Dorsey Wright Healthcare Momentum ETF
占比3.38%
TrueShares Technology, AI & Deep Learning ETF
占比3.21%
First Trust NYSE Arca Biotechnology Index Fund
占比3.12%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
常见问题
Natera Inc的前五大股东是谁？
Natera Inc 的前五大股东如下：
The Vanguard Group, Inc.持有股份：12.62M，占总股份比例：9.20%。
T. Rowe Price Associates, Inc.持有股份：12.07M，占总股份比例：8.79%。
JP Morgan Asset Management持有股份：8.92M，占总股份比例：6.50%。
BlackRock Institutional Trust Company, N.A.持有股份：6.78M，占总股份比例：4.94%。
Farallon Capital Management, L.L.C.持有股份：4.82M，占总股份比例：3.51%。
The Vanguard Group, Inc.持有股份：12.62M，占总股份比例：9.20%。
T. Rowe Price Associates, Inc.持有股份：12.07M，占总股份比例：8.79%。
JP Morgan Asset Management持有股份：8.92M，占总股份比例：6.50%。
BlackRock Institutional Trust Company, N.A.持有股份：6.78M，占总股份比例：4.94%。
Farallon Capital Management, L.L.C.持有股份：4.82M，占总股份比例：3.51%。
Natera Inc的前三大股东类型是什么？
Natera Inc 的前三大股东类型分别是：
The Vanguard Group, Inc.
T. Rowe Price Associates, Inc.
JP Morgan Asset Management
The Vanguard Group, Inc.
T. Rowe Price Associates, Inc.
JP Morgan Asset Management
有多少机构持有Natera Inc(NTRA)的股份？
截至2025Q3，共有1200家机构持有Natera Inc的股份，合计持有的股份价值约为128.93M，占公司总股份的93.94%。与2025Q2相比，机构持股有所增加，增幅为-2.70%。
哪个业务部门对Natera Inc的收入贡献最大？
在FY2025Q2，Insurance carriers业务部门对Natera Inc的收入贡献最大，创收516.99M，占总收入的94.58%。
